Diversified Healthcare Trust (DHCNL) stock analysis
Close on Oct 30, 2026Market cap $1.93BP/E –Yield 0.50%
StockData Score
Prices as of Oct 30, 2026How the score works
Weak1 of 30 checks passed
Diversified Healthcare Trust passes 1 of the 30 checks behind our score; 15 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 0/6
- Past performance
- 0/6
- Financial health
- 0/6
- Dividend
- 1/6
What stands out
Pays a dividend
Diversified Healthcare Trust paid dividends worth 0.5% of the share price over the last twelve months.
What to watch
Margin of safety under 20%
The price is 78.9% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $7.97 is above our fair value estimate of $4.45.
Return on equity under 15%
Return on equity was -15.5% over the last twelve months and averaged -7.7% over five years; we look for 15% on both.
Revenue growing under 10% a year
Revenue grew 6.2% a year over the last three fiscal years, short of the 10% we look for.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA above its 5-year median
Diversified Healthcare Trust's EV/EBITDA of 14.5 is above its 5-year median of 4.3.
P/B above the industry
Diversified Healthcare Trust's price-to-book of 1.22 is above the Miscellaneous Investing median of 1.20.
Trading above fair value
The share price of $7.97 is above our fair value estimate of $4.45.
Margin of safety under 20%
The price is 78.9% above fair value, so there is no margin of safety.
Growth0/6
Revenue growing under 10% a year
Revenue grew 6.2% a year over the last three fiscal years, short of the 10% we look for.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew -1.5% over the last twelve months; the Miscellaneous Investing median is 4.4%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.
Past performance0/6
Return on equity under 15%
Return on equity was -15.5% over the last twelve months and averaged -7.7% over five years; we look for 15% on both.
Return on invested capital
Needs operating income and invested capital.
Return on equity below the industry
Diversified Healthcare Trust's return on equity of -15.5% is below the Miscellaneous Investing median of 3.4%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin below its 5-year average
Net margin was -17.7% over the last twelve months, against a 5-year average of -10.6%.
Net margin below the industry
Diversified Healthcare Trust's net margin of -17.7% is below the Miscellaneous Investing median of 11.4%.
Financial health0/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest coverage
Interest expense is not reported separately.
Short-term liquidity
The balance sheet is not split into current and non-current items.
Elevated bankruptcy risk
The Altman Z-score is 1.13; above 3 is the safe zone and below 1.8 the distress zone.
Dividend1/6
Pays a dividend
Diversified Healthcare Trust paid dividends worth 0.5% of the share price over the last twelve months.
Yield below Treasuries
The 0.5% yield is below the 4.4% on a 1-year Treasury.
Yield below the top quarter
The top quarter of US dividend payers yield 4.0% or more; Diversified Healthcare Trust yields 0.5%.
Dividend was cut
The dividend per share fell by more than 10% at least once in the last 10 fiscal years.
Earnings cover
Needs dividends paid and net income.
Cash-flow cover
Needs dividends paid and free cash flow.
Fair value
How we estimate itOur estimate per share
$4.45
The share price is 79% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| EV/EBITDA | 7.4× | 4.3× | 10.5× | $4.31 | 78% |
| P/B | 0.8× | 0.3× | 1.2× | $4.95 | 22% |
| Earnings powerleft out, too far from the others | 10.4% cost of equity | – | – | $1.36 | – |
| Fair value | $4.45 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Miscellaneous Investing median 25.0
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $15.31M
- Value traded per 1% price move
- $9.23M
Downside
Low risk
- Typical loss in a bad month
- 14.3%
- Volatility (annualized)
- 38%
- Sharpe ratio, 1 year
- 2.27
- Beta to the S&P 500 (5Y)
- 1.09
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +2.8% | +6.2% | -1.2% | +4.4% | |
| Dividend per share | 0.0% | 0.0% | -26.0% | -30.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 4.3% | -5.3% | -15.8% | |
| Return on assets | 2.0% | -2.1% | -6.0% | |
| Interest coverage | 1.8× | – | – | |
| Diluted shares | 237M | 238M | 240M |
Cash use needs five years of cash flow figures
Diversified Healthcare Trust does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -18.6% | 0.32× | 2.62× | -15.8% |
| FY2024 | -24.8% | 0.28× | 2.46× | -17.2% |
| FY2023 | -20.8% | 0.25× | 2.30× | -11.8% |
| FY2022 | -1.2% | 0.20× | 2.38× | -0.6% |
| FY2021 | 12.6% | 0.21× | 2.54× | 6.8% |
| FY2020 | -8.5% | 0.25× | 2.51× | -5.3% |
| FY2019 | -8.5% | 0.15× | 2.40× | -3.1% |
| FY2018 | 25.7% | 0.15× | 2.36× | 9.4% |
| FY2017 | 13.7% | 0.15× | 2.30× | 4.7% |
| FY2016 | 13.4% | 0.15× | 2.19× | 4.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$285.89M
- Cash generatingOperating cash flow above zero-$19.62M
- Return on assets improvedROA up on the prior year-6.8% → -5.6%
- Earnings backed by cashOperating cash flow above net income-$19.62M vs -$285.89M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose– → –
- No dilutionShare count did not rise240M → 240M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.27 → 0.30